0	14	Glucocorticoid	glucocorticoid	NN
15	24	receptors	receptor	NNS
25	28	are	be	VBP
29	43	down-regulated	down-regulate	VBN
44	46	in	in	IN
47	55	inflamed	inflamed	JJ
56	63	colonic	colonic	JJ
64	70	mucosa	mucosa	NN
71	74	but	but	CC
75	78	not	not	RB
79	81	in	in	IN
82	92	peripheral	peripheral	JJ
93	98	blood	blood	NN
99	110	mononuclear	mononuclear	JJ
111	116	cells	cell	NNS
117	121	from	from	IN
122	130	patients	patient	NNS
131	135	with	with	IN
136	148	inflammatory	inflammatory	JJ
149	154	bowel	bowel	NN
155	162	disease	disease	NN
163	164	[	[	(
164	167	see	see	VB
168	176	comments	comment	NNS
176	177	]	]	)
179	189	BACKGROUND	BACKGROUND	NNP
189	190	:	:	:
191	198	Growing	grow	VBG
199	207	evidence	evidence	NN
208	217	indicates	indicate	VBZ
218	222	that	that	IN
223	226	the	the	DT
227	233	immune	immune	JJ
234	240	system	system	NN
241	244	and	and	CC
245	248	the	the	DT
249	279	hypothalamic-pituitary-adrenal	hypothalamic-pituitary-adrenal	JJ
280	286	system	system	NN
287	290	are	be	VBP
291	297	linked	link	VBN
298	300	by	by	IN
301	308	several	several	JJ
309	319	mechanisms	mechanism	NNS
319	320	,	,	,
321	324	for	for	IN
325	332	example	example	NN
333	346	intracellular	intracellular	JJ
347	361	glucocorticoid	glucocorticoid	NN
362	371	receptors	receptor	NNS
372	373	(	(	(
373	376	hGR	hGR	NNP
376	377	)	)	)
377	378	.	.	.

379	394	Glucocorticoids	glucocorticoid	NNS
395	398	are	be	VBP
399	402	the	the	DT
403	411	standard	standard	JJ
412	421	treatment	treatment	NN
422	424	of	of	IN
425	430	acute	acute	JJ
431	438	attacks	attack	NNS
439	441	of	of	IN
442	454	inflammatory	inflammatory	JJ
455	460	bowel	bowel	NN
461	468	disease	disease	NN
469	470	(	(	(
470	473	IBD	IBD	NNP
473	474	)	)	)
474	475	.	.	.

476	483	Binding	binding	NN
484	486	of	of	IN
487	502	glucocorticoids	glucocorticoid	NNS
503	505	to	to	TO
506	509	hGR	hGR	NNP
510	524	down-regulates	down-regulate	VBZ
525	528	the	the	DT
529	542	transcription	transcription	NN
543	545	of	of	IN
546	558	inflammatory	inflammatory	JJ
559	564	genes	gene	NNS
565	569	that	that	WDT
570	573	can	can	MD
574	583	propagate	propagate	VB
584	587	IBD	ibd	NN
587	588	.	.	.

589	597	PATIENTS	patients	NNS
598	601	AND	and	CC
602	609	METHODS	methods	NNS
609	610	:	:	:
611	614	IBD	IBD	NNP
615	623	patients	patient	NNS
624	628	were	be	VBD
629	635	either	either	RB
636	643	treated	treat	VBN
644	648	with	with	IN
649	653	5-60	5-60	CD
654	656	mg	mg	NN
657	659	of	of	IN
660	672	prednisolone	prednisolone	NN
673	676	for	for	IN
677	681	more	more	JJR
682	686	than	than	IN
687	688	1	1	CD
689	693	week	week	NN
694	696	or	or	CC
697	701	were	be	VBD
702	709	without	without	IN
710	724	glucocorticoid	glucocorticoid	NN
725	734	treatment	treatment	NN
735	738	for	for	IN
739	743	more	more	JJR
744	748	than	than	IN
749	750	4	4	CD
751	757	weeks.	weeks.	NN
758	761	hGR	hGR	NNP
762	768	levels	level	NNS
769	773	were	be	VBD
774	784	determined	determine	VBN
785	789	from	from	IN
790	798	isolated	isolate	VBN
799	806	cytosol	cytosol	NN
807	809	of	of	IN
810	820	peripheral	peripheral	JJ
821	826	blood	blood	NN
827	838	mononuclear	mononuclear	JJ
839	844	cells	cell	NNS
845	846	(	(	(
846	851	PBMCs	PBMC	NNPS
851	852	)	)	)
853	855	or	or	CC
856	863	mucosal	mucosal	JJ
864	872	biopsies	biopsy	NNS
873	878	using	use	VBG
879	880	a	a	DT
881	891	radioassay	radioassay	NN
892	896	with	with	IN
897	898	[	[	(
898	915	3H]-dexamethasone	3H]-dexamethasone	NNP
915	916	.	.	.

917	928	Interleukin	Interleukin	NNP
929	930	(	(	(
930	932	IL	IL	NNP
932	933	)	)	)
934	935	6	6	CD
936	942	levels	level	NNS
943	947	were	be	VBD
948	958	determined	determine	VBN
959	961	by	by	IN
962	975	enzyme-linked	enzyme-linked	JJ
976	989	immunosorbent	immunosorbent	JJ
990	995	assay	assay	NN
996	997	(	(	(
997	1004	ELISA).	ELISA).	NNP
1005	1012	RESULTS	RESULTS	NNP
1012	1013	:	:	:
1014	1017	The	the	DT
1018	1026	systemic	systemic	JJ
1027	1028	(	(	(
1028	1032	PBMC	PBMC	NNP
1032	1033	)	)	)
1034	1037	hGR	hGR	NNP
1038	1044	levels	level	NNS
1045	1047	of	of	IN
1048	1070	corticosteroid-treated	corticosteroid-treated	JJ
1071	1074	IBD	IBD	NNP
1075	1083	patients	patient	NNS
1084	1088	were	be	VBD
1089	1102	significantly	significantly	RB
1103	1108	lower	low	JJR
1109	1113	than	than	IN
1114	1119	those	those	DT
1120	1122	of	of	IN
1123	1130	control	control	JJ
1131	1139	subjects	subject	NNS
1140	1141	(	(	(
1141	1145	59.6	59.6	CD
1146	1149	+/-	+/-	SYM
1150	1154	57.1	57.1	CD
1155	1158	dpm	dpm	NN
1159	1163	mg-1	mg-1	NN
1164	1171	cytosol	cytosol	NN
1172	1179	protein	protein	NN
1180	1183	vs.	vs.	IN
1184	1189	227.0	227.0	CD
1190	1193	+/-	+/-	SYM
1194	1198	90.8	90.8	CD
1199	1202	dpm	dpm	NN
1203	1207	mg-1	mg-1	NN
1208	1215	cytosol	cytosol	NN
1216	1223	protein	protein	NN
1223	1224	,	,	,
1225	1226	P	p	NN
1227	1228	=	=	SYM
1229	1234	0.007	0.007	CD
1234	1235	)	)	)
1236	1239	and	and	CC
1240	1243	IBD	IBD	NNP
1244	1252	patients	patient	NNS
1253	1256	not	not	RB
1257	1266	receiving	receive	VBG
1267	1281	glucocorticoid	glucocorticoid	NN
1282	1291	treatment	treatment	NN
1292	1293	(	(	(
1293	1298	179.7	179.7	CD
1299	1302	+/-	+/-	SYM
1303	1308	171.3	171.3	CD
1309	1312	dpm	dpm	NN
1313	1317	mg-1	mg-1	NN
1318	1325	cytosol	cytosol	NN
1326	1333	protein	protein	NN
1333	1334	,	,	,
1335	1336	P	p	NN
1337	1338	=	=	SYM
1339	1344	0.002	0.002	CD
1344	1345	)	)	)
1345	1346	.	.	.

1347	1355	Systemic	systemic	JJ
1356	1359	hGR	hGR	NNP
1360	1366	levels	level	NNS
1367	1369	in	in	IN
1370	1379	untreated	untreated	JJ
1380	1383	IBD	IBD	NNP
1384	1392	patients	patient	NNS
1393	1396	did	do	VBD
1397	1400	not	not	RB
1401	1407	differ	differ	VB
1408	1421	significantly	significantly	RB
1422	1426	from	from	IN
1427	1432	those	those	DT
1433	1435	in	in	IN
1436	1443	control	control	JJ
1444	1452	subjects	subject	NNS
1452	1453	.	.	.

1454	1456	In	in	IN
1457	1465	patients	patient	NNS
1466	1470	with	with	IN
1471	1481	connective	connective	JJ
1482	1488	tissue	tissue	NN
1489	1497	diseases	disease	NNS
1497	1498	,	,	,
1499	1507	systemic	systemic	JJ
1508	1511	hGR	hGR	NNP
1512	1518	levels	level	NNS
1519	1523	were	be	VBD
1524	1528	also	also	RB
1529	1534	found	find	VBN
1535	1537	to	to	TO
1538	1540	be	be	VB
1541	1550	decreased	decrease	VBN
1551	1553	in	in	IN
1554	1557	the	the	DT
1558	1565	absence	absence	NN
1566	1568	of	of	IN
1569	1583	glucocorticoid	glucocorticoid	NN
1584	1593	treatment	treatment	NN
1593	1594	.	.	.

1595	1603	Systemic	systemic	JJ
1604	1607	hGR	hGR	NNP
1608	1614	levels	level	NNS
1615	1617	in	in	IN
1618	1626	patients	patient	NNS
1627	1631	with	with	IN
1632	1637	Crohn	Crohn	NNP
1637	1639	’s	's	POS
1640	1647	disease	disease	NN
1648	1649	(	(	(
1649	1651	CD	cd	NN
1651	1652	)	)	)
1653	1660	treated	treat	VBN
1661	1665	with	with	IN
1666	1674	steroids	steroid	NNS
1675	1676	(	(	(
1676	1680	66.6	66.6	CD
1681	1684	+/-	+/-	SYM
1685	1689	61.0	61.0	CD
1690	1693	dpm	dpm	NN
1694	1698	mg-1	mg-1	NN
1699	1706	cytosol	cytosol	NN
1707	1714	protein	protein	NN
1714	1715	)	)	)
1716	1720	were	be	VBD
1721	1724	not	not	RB
1725	1734	different	different	JJ
1735	1739	from	from	IN
1740	1745	those	those	DT
1746	1748	in	in	IN
1749	1757	patients	patient	NNS
1758	1762	with	with	IN
1763	1773	ulcerative	ulcerative	JJ
1774	1781	colitis	colitis	NN
1782	1783	(	(	(
1783	1785	UC	UC	NNP
1785	1786	)	)	)
1787	1788	(	(	(
1788	1792	56.1	56.1	CD
1793	1796	+/-	+/-	SYM
1797	1801	51.6	51.6	CD
1802	1805	dpm	dpm	NN
1806	1810	mg-1	mg-1	NN
1811	1818	cytosol	cytosol	NN
1819	1826	protein	protein	NN
1826	1827	)	)	)
1827	1828	.	.	.

1829	1831	In	in	IN
1832	1840	contrast	contrast	NN
1841	1843	to	to	TO
1844	1849	these	these	DT
1850	1858	findings	finding	NNS
1858	1859	,	,	,
1860	1867	mucosal	mucosal	JJ
1868	1871	hGR	hGR	NNP
1872	1878	levels	level	NNS
1879	1883	were	be	VBD
1884	1897	significantly	significantly	RB
1898	1907	decreased	decrease	VBN
1908	1910	in	in	IN
1911	1915	both	both	CC
1916	1931	steroid-treated	steroid-treated	JJ
1932	1933	(	(	(
1933	1937	18.0	18.0	CD
1938	1941	+/-	+/-	CC
1942	1946	15.5	15.5	CD
1946	1947	)	)	)
1948	1951	and	and	CC
1952	1955	not	not	RB
1956	1971	steroid-treated	steroid-treated	JJ
1972	1973	(	(	(
1973	1977	37.8	37.8	CD
1978	1981	+/-	+/-	CC
1982	1986	30.5	30.5	CD
1986	1987	)	)	)
1988	1996	patients	patient	NNS
1997	2005	compared	compare	VBN
2006	2010	with	with	IN
2011	2018	control	control	JJ
2019	2027	subjects	subject	NNS
2028	2029	(	(	(
2030	2035	125.6	125.6	CD
2036	2039	+/-	+/-	CC
2040	2044	97.1	97.1	CD
2044	2045	;	;	:
2046	2047	P	p	NN
2048	2049	=	=	SYM
2050	2057	0.00009	0.00009	CD
2058	2061	and	and	CC
2062	2063	P	p	NN
2064	2065	=	=	SYM
2066	2072	0.0008	0.0008	CD
2073	2085	respectively	respectively	RB
2086	2087	)	)	)
2087	2088	.	.	.

2089	2093	IL-6	il-6	NN
2094	2100	levels	level	NNS
2101	2103	in	in	IN
2104	2107	all	all	DT
2108	2111	IBD	ibd	NN
2112	2118	groups	group	NNS
2119	2123	with	with	IN
2124	2127	and	and	CC
2128	2135	without	without	IN
2136	2144	steroids	steroid	NNS
2145	2149	were	be	VBD
2150	2163	significantly	significantly	RB
2164	2173	different	different	JJ
2174	2178	from	from	IN
2179	2184	those	those	DT
2185	2187	in	in	IN
2188	2195	control	control	JJ
2196	2204	subjects	subject	NNS
2204	2205	.	.	.

2206	2216	CONCLUSION	conclusion	NN
2216	2217	:	:	:
2218	2220	In	in	IN
2221	2224	IBD	IBD	NNP
2225	2230	there	there	EX
2231	2233	is	be	VBZ
2234	2236	no	no	DT
2237	2247	difference	difference	NN
2248	2250	in	in	IN
2251	2259	systemic	systemic	JJ
2260	2263	hGR	hGR	NNP
2264	2270	levels	level	NNS
2271	2278	between	between	IN
2279	2282	not	not	RB
2283	2298	steroid-treated	steroid-treated	JJ
2299	2307	patients	patient	NNS
2308	2311	and	and	CC
2312	2319	control	control	JJ
2320	2328	subjects	subject	NNS
2328	2329	,	,	,
2330	2332	in	in	IN
2333	2338	spite	spite	NN
2339	2341	of	of	IN
2342	2354	inflammatory	inflammatory	JJ
2355	2363	activity	activity	NN
2364	2365	(	(	(
2365	2369	IL-6	IL-6	NNP
2369	2370	)	)	)
2370	2371	.	.	.

2372	2379	Mucosal	mucosal	JJ
2380	2383	hGR	hGR	NNP
2384	2390	levels	level	NNS
2391	2395	were	be	VBD
2396	2405	decreased	decrease	VBN
2406	2419	independently	independently	RB
2420	2422	of	of	IN
2423	2432	treatment	treatment	NN
2432	2433	,	,	,
2434	2442	probably	probably	RB
2443	2450	leading	lead	VBG
2451	2453	to	to	TO
2454	2455	a	a	DT
2456	2465	decreased	decrease	VBN
2466	2476	protection	protection	NN
2477	2484	against	against	IN
2485	2494	NF-kappaB	NF-kappaB	NNP
2495	2501	action	action	NN
2502	2504	in	in	IN
2505	2508	the	the	DT
2509	2519	intestinal	intestinal	JJ
2520	2526	mucosa	mucosa	NN
2526	2527	.	.	.